miR-486 is an epigenetic modulator of Duchenne muscular dystrophy pathologies.

Eclipsebio's eCOMPASS platform combines AI-optimized design and sequencing-based analytics to produce successful RNA therapeutics efficiently.

eCOMPASS guides drug developers to the optimal candidate with its lap-in-the-loop platform.

Successful lab-in-the-loop approaches optimize RNA therapeutic design to be easily manufactured and produced.

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.